Research

The Chase Family Movement Disorders Center offers opportunities for active participation in cutting edge research in the field through clinical trials.

These studies are conducted in collaboration with other movement disorders specialists throughout North America and Europe. We have several ongoing clinical research studies as noted below, and all patients have the option to participate in one or more clinical trials.

We are also involved in mentoring students and physicians-in-training who will serve the community in the future as neurologists, researchers, or in primary care. 

Clinical Trials

The Chase Family Movement Disorders Center continues to seek new ways to slow the progression of neurodegenerative disorders through clinical trials in collaboration with other movement disorders specialists throughout North America.

We have several ongoing clinical research studies as noted below, and all patients have the option to participate in one or more clinical trials. We are also involved in mentoring physicians-in-training who will serve the community in the future as neurologists or in primary care.

1. Protocol No: IN 11 004 (enrolling)

A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study comparing the efficacy and safety of gastric retentive, controlled release Accordian pill™ carbidopa/levodopa (AP CD/LD) to immediate release CD/LD in fluctuating Parkinson's disease patients.

Looking for patients with at least 2.5 hours of OFF timer per day, on at least 4 does of levodopa per day plus another anti-PD medication.

2. Protocol No: IN 11 004 OLE (roll-over) 

An open-label, multicenter follow-up study designed to evaluate long term effects of Accordian pill™ carbidopa/levodopa (AP CD/LD) in fluctuating Parkinson's disease patients who completed study in 11 004. This is the open label extension to the above mentioned study.

3. Protocol No: Eli Lilly 17S-MC-HBEH (pending Feb/Mar. 2018) 

The Effect of LY3154207  on Cognition in Mild-to-Moderate Parkinson’s Disease Dementia (PDD)

4. Protocol No: P2B001/003 (enrolling) 

A Phase 3, 12 week, multi-center, multinational, Randomized, Double Blind, Double Dummy, Parallel Group Study to determine the Efficacy, Safety, and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects with Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER. 

No placebo arm to this study.  Looking for de novo patients up to 75 years of age.

Chase Family Movement Disorders Center

  • Contact Us

    Phone: 860.870.6385
    Fax: 860.870.0625
  • Help our patients continue to do the things that they need to do and like to do.

    We're passionate about enhancing our patients’ lives, so we are developing a patient-driven program to meet the needs expressed by patients themselves. Can you help?

    Donate Now >>